HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
Song Yang,Huichun Xing,Yuming Wang,Jinlin Hou,Duande Luo,Qing Xie,Qin Ning,Hong Ren,Huiguo Ding,Jifang Sheng,Lai Wei,Shijun Chen,Xiaoling Fan,Wenxiang Huang,Chen Pan,Zhiliang Gao,Jiming Zhang,Boping Zhou,Guofeng Chen,Mobin Wan,Hong Tang,Guiqiang Wang,Yuxiu Yang,Dongping Xu,Peiling Dong,Qixin Wang,Jue Wang,Fernando A. Bognar,Daozhen Xu,Jun Cheng
DOI: https://doi.org/10.1186/s12985-016-0640-1
IF: 5.916
2016-01-01
Virology Journal
Abstract:Background This study aimed to evaluate the predictive values of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels in 171 Chinese patients with chronic hepatitis B who received a 48-week course of pegylated interferon alfa-2b therapy at 1.5 mcg/kg. Methods HBsAg, HBeAg, and hepatitis B virus (HBV) DNA levels were measured at baseline and weeks 12, 24, 48, and 72. Clinical responses were defined as a combined response (CR, HBeAg seroconversion [sustained response, SR] combined with HBV DNA level <2,000 IU/mL at week 72). The positive predictive value and negative predictive value were calculated for HBsAg alone and/or combined with HBeAg and HBV DNA at weeks 12 and 24. Results Of 171 patients included, 58 (33.9 %) achieved a SR. Of patients who achieved a SR, 33 (56.9 %) achieved a CR. Totally 19.3 % (33/171) patients achieved CR and 80.7 % (138/171) patients did not. Patients with HBsAg <1500 IU/mL at week 12 had a 47.4 % chance of achieving an off-treatment SR and patients with a HBsAg decrease >1.5 logIU/mL at week 12 had a 54.5 % chance. Patients with HBsAg >20,000 IU/mL at weeks 12 and 24 had a 93.8 and 100.0 % chance, respectively, of not achieving a CR. An HBsAg level or changes at weeks 12 and 24, combined with HBeAg or HBV DNA, increased the chance for a SR and CR. Conclusions On-treatment HBsAg quantification, alone or in combination with HBeAg or HBV DNA, predicted off-treatment SR and CR after 48 weeks of PEG-IFNα-2b therapy, and thus, may guide clinicians in making a therapeutic decision to continue or terminate the therapy.